FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus che...
28 Nov 202345min
It's time to talk about sexual health and lung cancer!
Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common in people with lung cancer, with many receiving ver...
28 Nov 202339min
Virtual Tumor Board: Neoadjuvant for Stage III NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virtual tumor board format. This area has become incre...
21 Nov 202347min
LCC in Dutch: Lung Cancer Care in The Netherlands
This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and is hosted by Dr. Lizza Hendriks from the Maastricht...
17 Nov 202353min
AEGEAN and Beyond: Perioperative Immunotherapy for NSCLC
Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients wit...
14 Nov 202340min
Updated IASLC - Hindi
Title: Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast) The podcast is recorded in Hindi and covers a range of crucial lung cancer topics, including the emergen...
10 Nov 202350min
FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC
In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA granted approval to encorafenib and binime...
6 Nov 202342min
ESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and...
1 Nov 202345min
